Evommune, Inc.
EVMN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002044725
No open-market purchases or sales by Evommune, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $462.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Evommune, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Evommune, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pena Luis C. | President & CEO | 631,573 | Oct 15, 2026 | 5 |
| Carver Kyle | Chief Financial Officer | 60,335 | Jul 10, 2026 | 4 |
| Kirsch Arthur S | Director | 10,000Indirect | Jul 8, 2026 | 2 |
| Drew Janice Suzann | Chief of Dev. Operations | 67,794 | Jun 24, 2026 | 3 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 46,403 | Jun 24, 2026 | 4 |
| McGraw Benjamin F III | Director | – | Jun 3, 2026 | 1 |
| Cohen David E | Director | 17,609 | Jun 3, 2026 | 1 |
| Moss Gregory S. | Chief Business & Legal Officer | 60,835 | Jun 1, 2026 | 3 |
| Bauer Eugene | Chief Medical Officer | 270,818 | Apr 17, 2026 | 3 |
| LSP 7 Cooperative UA | Director, 10% Owner | 5,288,313Indirect | Feb 19, 2026 | 1 |
| Verduyn-van Weegen Felice Isabel | Director, 10% Owner | 5,288,313Indirect | Feb 18, 2026 | 1 |
| RA Capital Healthcare Fund LP | Director | 2,710,293Indirect | Feb 17, 2026 | 1 |
| Ra Capital Management, L.P. | Director | 2,710,293Indirect | Feb 17, 2026 | 1 |
| Kolchinsky Peter | Director | 2,710,293Indirect | Feb 17, 2026 | 1 |
| Shah Rajeev M. | Director | 2,710,293Indirect | Feb 17, 2026 | 1 |
| RA Capital Nexus Fund III, L.P. | Director | 2,710,293Indirect | Feb 17, 2026 | 1 |
| Hopfner Robert Lorne | Director, 10% Owner | 4,026Indirect | Dec 22, 2025 | 1 |
| Pivotal bioVenture Partners Fund I, L.P. | Director, 10% Owner | 294,502Indirect | Nov 12, 2025 | 0 |
| Pivotal bioVenture Partners Fund I U.G.P. Ltd | Director, 10% Owner | 294,502Indirect | Nov 12, 2025 | 0 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director, 10% Owner | 294,502Indirect | Nov 12, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)7:59 PM ET | Jul 8 | 2 days | Carver KyleChief Financial Officer | PPurchase | +1.00K | $13.26 | +$13.3K | +1.7%60.3K after | |
| Jul 8, 2026 (view filing)8:00 PM ET | Jul 7 | 1 day | Kirsch Arthur SDirector | PPurchase | +10.0K | $13.30 | +$133.0K | New position10.0K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Patel Jeegar PravinkumarChief Scientific Officer | SSale | −1.49K | $22.50 | −$33.5K | −3.1%46.4K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Drew Janice SuzannChief of Dev. Operations | SSale | −20.0K | $22.63 | −$452.6K | −22.8%67.8K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Pena Luis C.President & CEO | SSale | −7.44K | $22.71 | −$168.9K | −1.2%630.5K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Patel Jeegar PravinkumarChief Scientific Officer | SSale | −16.7K | $22.74 | −$379.5K | −26.4%46.4K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Pena Luis C.President & CEO | SSale | −16.8K | $22.74 | −$381.7K | −2.6%637.9K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Cohen David EDirector | SSale | −6.06K | $20.33 | −$123.1K | −25.6%17.6K after | 2 lots10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Carver KyleChief Financial Officer | SSale | −18.2K | $22.84 | −$415.1K | −23.4%59.3K after | 10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Moss Gregory S.Chief Business & Legal Officer | SSale | −14.2K | $22.83 | −$324.7K | −18.9%60.8K after | 10b5-1 |
| Dec 22, 2025 (view filing) | Dec 19 | 3 days | Hopfner Robert LorneDirector, 10% Owner | PPurchase | +1.00K | $17.35 | +$17.4K | +33.0%4.03K after | |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | Verduyn-van Weegen Felice IsabelDirector, 10% Owner | PPurchase | +1.56M | $16.00 | +$25.0M | +46.4%4.93M after | Duplicate filing |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | LSP 7 Cooperative UA10% Owner | PPurchase | +1.56M | $16.00 | +$25.0M | +46.4%4.93M after | |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | Ra Capital Management, L.P.Director, 10% Owner | PPurchase | +1.25M | $16.00 | +$20.0M | New position784.3K after | 2 lots |